Dishman Carbogen Amcis Limited has informed the Exchange regarding a press release dated February 04, 2026, titled "PRESS RELEASE ON UN-AUDITED FINANCIAL RESULT FOR THE THIRD QUARTER ENDED 31ST DECEMBER, 2025 REGULATIONS: 30 and 51".
DCAL · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Dishman Carbogen Amcis has informed the stock exchanges about a press release dated February 4, 2026, covering its unaudited financial results for the third quarter ended December 31, 2025. The disclosure has been made under SEBI Listing Regulations 30 and 51, which cover material events and financial results submissions. Specific revenue, profit, or margin figures are not available in this filing excerpt and would be detailed in the attached press release. The company, a pharmaceutical contract development and manufacturing player, typically reports results followed by an investor call and analyst commentary.
This is a routine regulatory disclosure accompanying the Q3 earnings release. Shareholders should look at the detailed press release for actual revenue, EBITDA, and PAT figures to gauge quarterly performance and any impact on stock price. The regulatory compliance itself is neutral — no immediate price catalyst unless results materially beat or miss expectations.